Premium
IC‐01‐01: Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease
Author(s) -
Hinrichs Anthony L.,
Mintun Mark,
Head Denise,
Fagan Anne M.,
Holtzman David M.,
Morris John C.,
Goate Alison
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.2487
Subject(s) - heritability , endophenotype , intraclass correlation , missing heritability problem , psychology , biomarker , genome wide association study , trait , genetic association , genetics , oncology , genotype , biology , neuroscience , medicine , gene , developmental psychology , single nucleotide polymorphism , psychometrics , cognition , computer science , programming language
may be difficult to achieve. Nevertheless, imaging and biochemical biomarkers may together provide convincing evidence that a given treatment at a given dose does impact amyloid plaque in brain parenchyma or soluble A in the central compartment, thus providing support for the initiation of long and costly Phase 3 studies. Diagnostic biomarkers including amyloid imaging and cerebrospinal fluid biochemical studies were considered for patients with mild cognitive impairment or for cognitively normal individuals 60 years of age or older. Data from economic models will be presented showing the impact of early diagnosis using these biomarkers on subsequent total costs related to AD, assuming the availability of disease-modifying treatments. Conclusions: Imaging and biochemical biomarkers are techniques that have important roles when applied to the drug development process. In addition to providing important Phase 2 data leading to better decision making for Phase 3 development, imaging and biochemical biomarkers may provide important data to identify which patient populations could benefit most from disease-modifying treatments. While pharma companies may not develop biomarker technologies themselves, close collaboration with academic groups and diagnostic companies can foster these efforts.